Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm

被引：28
作者：
Berghmans, Thierry [1 ]
Dingemans, Anne-Marie [2 ,3 ]
Hendriks, Lizza E. L. [2 ]
Cadranel, Jacques [4 ,5 ]
机构：
[1] Univ Libre Bruxelles, Inst Jules Bordet, Thorac Oncol Clin, Brussels, Belgium
[2] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol, Dept Pulm Dis GROW, Maastricht, Netherlands
[3] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands
[4] Hop Tenon, AP HP, Serv Pneumol, Paris, France
[5] Sorbonne Univ, Paris, France
来源：
EUROPEAN RESPIRATORY JOURNAL | 2020年 / 55卷 / 02期
关键词：
IMMUNE CHECKPOINT INHIBITORS; OPEN-LABEL; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.1183/13993003.01907-2019
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：5
相关论文
共 32 条
  • [1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [2] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
    Ayers, Mark
    Lunceford, Jared
    Nebozhyn, Michael
    Murphy, Erin
    Loboda, Andrey
    Kaufman, David R.
    Albright, Andrew
    Cheng, Jonathan D.
    Kang, S. Peter
    Shankaran, Veena
    Piha-Paul, Sarina A.
    Yearley, Jennifer
    Seiwert, Tanguy Y.
    Ribas, Antoni
    McClanahan, Terrill K.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) : 2930 - 2940
  • [3] Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma
    Berghmans, T.
    Grigoriu, B.
    Sculier, J. P.
    Meert, A. P.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2018, 35 (02) : 197 - 205
  • [4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
    Brahmer, Julie
    Reckamp, Karen L.
    Baas, Paul
    Crino, Lucio
    Eberhardt, Wilfried E. E.
    Poddubskaya, Elena
    Antonia, Scott
    Pluzanski, Adam
    Vokes, Everett E.
    Holgado, Esther
    Waterhouse, David
    Ready, Neal
    Gainor, Justin
    Aren Frontera, Osvaldo
    Havel, Libor
    Steins, Martin
    Garassino, Marina C.
    Aerts, Joachim G.
    Domine, Manuel
    Paz-Ares, Luis
    Reck, Martin
    Baudelet, Christine
    Harbison, Christopher T.
    Lestini, Brian
    Spigel, David R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
  • [6] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [7] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Chen, Daniel S.
    Irving, Bryan A.
    Hodi, F. Stephen
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6580 - 6587
  • [8] Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
    Cook, Michael R.
    Kim, Chul
    [J]. JAMA ONCOLOGY, 2019, 5 (07) : 1049 - 1054
  • [9] DAY C, 2018, ANN ONCOL S8, V29
  • [10] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
    Fehrenbacher, Louis
    Spira, Alexander
    Ballinger, Marcus
    Kowanetz, Marcin
    Vansteenkiste, Johan
    Mazieres, Julien
    Park, Keunchil
    Smith, David
    Artal-Cortes, Angel
    Lewanski, Conrad
    Braiteh, Fadi
    Waterkamp, Daniel
    He, Pei
    Zou, Wei
    Chen, Daniel S.
    Yi, Jing
    Sandler, Alan
    Rittmeyer, Achim
    [J]. LANCET, 2016, 387 (10030) : 1837 - 1846
1234